Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program ...

Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both ...

Biotech veteran Dr. Amit Rakhit shares his strategy for navigating global regulatory systems by embracing "strategic ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

A new market analysis projects the Heart Block Therapeutics Market will grow from an estimated USD 3.5 billion in 2025 to a ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

Before the Kansas City Chiefs became perennial Super Bowl contenders, Andy Reid led a textbook organizational turnaround.

New York hospitals that get discounted drugs through a controversial federal program are gearing up for a new pilot that they ...

A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer recently shed light on. When a caller noted that the ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...